Macrogenics Inc Dossier
Qualitative Analysis
Business overview
MacroGenics, Inc. (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company generates its pipeline primarily from its proprietary suite of next-generation antibody-based technology platforms, including its DART and TRIDENT multi-specific platforms and antibody-drug conjugate (ADC) technologies. MacroGenics has successfully contributed to three FDA-approved partner-marketed products (including ZYNYZ and TZIELD) and has established strategic collaborations with global pharmaceutical companies such as Gilead, Incyte, and Sanofi.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
MacroGenics entered into a definitive agreement to sell its GMP drug substance manufacturing operations in Rockville, Maryland, and Frederick, Maryland, to Bora Pharmaceuticals. This divestiture transitions MacroGenics into a more agile, clinical-stage biopharmaceutical company focused entirely on novel drug discovery and development.
Expected impact: Provides $122.5 million in upfront cash proceeds, transfers approximately 140 employees to Bora, and reduces internal operational complexity while maintaining pipeline manufacturing access via a long-term supply agreement.
Sharpening focus on high-value antibody-drug conjugates (ADCs) and multi-specific programs. This includes advancing clinical-stage ADCs MGC026 and MGC028, preparing the IND for MGC030, and continuing the Phase 2 LINNET study of lorigerlimab in ovarian cancer, while discontinuing less promising programs such as vobramitamab duocarmazine and the development of lorigerlimab in prostate cancer.
Expected impact: Optimizes capital allocation toward candidates with the highest probability of clinical and commercial success, extending the company's cash runway.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Enables MacroGenics to monetize its manufacturing infrastructure and CDMO operations while securing long-term process development and drug substance production support for its clinical pipeline.
Terms: MacroGenics will receive an upfront cash payment of $122.5 million upon closing, subject to customary conditions.
Monetizes the royalty stream of ZYNYZ (retifanlimab-dlwr) to secure immediate non-dilutive funding for pipeline development.
Terms: MacroGenics received a $60 million upfront cash payment in May 2026 and is eligible to receive an additional sales-based milestone of up to $20 million based on 2026 ZYNYZ sales performance. Royalty rights revert to MacroGenics after Sagard achieves capped return thresholds.
Gilead licensed an additional preclinical program leveraging MacroGenics' novel T-cell engager platform to improve safety and efficacy over traditional T-cell engagers.
Terms: Triggered a $25 million payment to MacroGenics in late 2025. MacroGenics remains eligible for up to $1.6 billion in future milestone payments plus royalties across three collaborative programs.